Abstract
BACKGROUND Aspiration thrombectomy in ST-segment elevation myocardial infarction is recommended by current guidelines based on several randomized trials. There are no trials assessing thrombectomy in non-ST-segment elevation myocardial infarction (NSTEMI) patients. OBJECTIVES The TATORT-NSTEMI (Thrombus Aspiration in Thrombus Containing Culprit Lesions in Non-ST-Elevation Myocardial Infarction) trial sought to assess the effect of aspiration thrombectomy on microvascular injury in patients with NSTEMI compared with standard percutaneous coronary intervention (PCI). METHODS This prospective, controlled, multicenter study randomized 440 patients to adjunctive thrombectomy (n = 221) compared with conventional PCI (n = 219) in NSTEMI patients with thrombus-containing lesions. The primary endpoint of the extent of microvascular obstruction (MO) in the percentage of left ventricular mass (%LV) was assessed by cardiac magnetic resonance imaging within 4 days. Secondary endpoints included infarct size, myocardial salvage index, and angiographic parameters including myocardial blush grade and Thrombolysis In Myocardial Infarction flow grade. The combined clinical endpoint consisted of death, reinfarction, target vessel revascularization, and new congestive heart failure within 6 months. RESULTS The primary endpoint of MO was not different between the thrombectomy and the standard PCI group with 2.0%LV (interquartile range [IQR]: 0.8 to 4.1) versus 1.4%LV (IQR: 0.7 to 2.6) (p = 0.17). Similarly, no significant differences were observed for infarct size (8.6%LV; IQR: 4.0 to 14.7 vs. 7.4%LV; IQR: 4.1 to 13.1; p = 0.46), myocardial salvage index (63.3; IQR: 35.4 to 87.2 vs. 65.6; IQR: 46.9 to 82.6; p = 0.45), or angiographic parameters such as blush grade (p = 0.63) and Thrombolysis In Myocardial Infarction flow grade (p = 0.66). Clinical follow-up at 6 months revealed no differences in the combined clinical endpoints (p = 0.22). CONCLUSIONS Aspiration thrombectomy in conjunction with PCI in NSTEMI with a thrombus-containing lesion does not lead to a reduction in MO.
| Original language | English |
|---|---|
| Journal | Journal of the American College of Cardiology |
| Volume | 64 |
| Issue number | 11 |
| Pages (from-to) | 1117-1124 |
| Number of pages | 8 |
| ISSN | 0735-1097 |
| DOIs | |
| Publication status | Published - 2014 |
Funding
The TATORT-NSTEMI trial is an investigator-initiated study that was supported by unrestricted grants from Terumo Europe, Leuven, Belgium; Daiichi-Sankyo , Munich, Germany; and Lilly Germany, Bad Homburg, Germany. The authors are solely responsible for the design and conduct of the study and all study analyses and the drafting and editing of the paper and its final contents. These companies had no influence on the study design, data collection, data analysis, and final drafting of this manuscript. Dr. Thiele has received grants from Eli Lilly and Terumo. Dr. Zeymer has received consulting and research grants from The Medicines Company and Terumo. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Research Areas and Centers
- Centers: Cardiological Center Luebeck (UHZL)
DFG Research Classification Scheme
- 2.22-12 Cardiology, Angiology
